The measure is designed to end surprise medical billing and balance billing, taking the first step to implement the so-called No Surprises Act that passed Congress at the end of last year.
The Biden administration announced an interim final rule Thursday designed to end surprise medical billing and balance billing, taking the first step to implement the so-called No Surprises Act that passed Congress at the end of last year.
“No patient should forgo care for fear of surprise billing,” said HHS Secretary Xavier Becerra in a statement. “Health insurance should offer patients peace of mind that they won’t be saddled with unexpected costs.”
These out-of-pocket costs stem from health care provided in emergency and nonemergency situations from clinicians who are out of the consumer’s network in employer-sponsored and commercial health plans.
Balance billing, which is already prohibited in both Medicare and Medicaid, is when a provider charges the remainder of what an insurance plan did not pay.
As noted in a recent article in The American Journal of Managed Care®, the issue has broad bipartisan appeal, as two-thirds of commercially insured adults worry about unexpected medical bills, the COVID-19 pandemic has created new medical needs, and narrow networks are becoming more common.
The interim final rule bans:
Other rulemaking will address the arbitration process, which will use an independent dispute resolution process. Arbitrators will be able to consider in-network benchmarks, and prohibits them from considering either billed charges or public payer rates. They can also take into account a physician’s training and experience, as well as the acuity of their patients and complexity of their case mix.
The 411-page interim final rule will be open for 60 days for public comment following its publication in the Federal Register and will take effect for group health plans and health insurance issuers on or after January 1, 2022.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Review Emphasizes Potential Infection Risks With BTK Inhibitors
November 2nd 2024Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract.
Read More
Health Equity & Access Weekly Roundup: November 2, 2024
November 2nd 2024This week’s Center on Health Equity & Access highlights emphasize the role of social determinants of health in policy-making and underscore the importance of addressing rising costs and challenges employers face.
Read More